ライフサイエンスコーパス: preclinical test

1 man skull porcine model was designed for the preclinical testing.

2 ation-competent adenoviruses are in advanced preclinical testing.

3 d clinical trials since 1998 and more are in preclinical testing.

4 elopment of lesion-specific therapeutics and preclinical testing.

5 nonhuman-primate organ transplant model for preclinical testing.

6 to identify a promising compound for further preclinical testing.

7 reases in insulin and GLP-1 secretion during preclinical testing.

8 ment with a number of compounds currently in preclinical testing.

9 ools available to researchers for systematic preclinical testing.

10 or mimicking human ADPKD and can be used for preclinical testing.

11 volunteers, which had not been predicted by preclinical testing.

12 ncer subtypes is critical to enable reliable preclinical testing.

13 decrease the likelihood of hepatotoxicity in preclinical testing.

14 y heart formation or may find application in preclinical testing.

15 uman immunodeficiency virus (HIV) vaccine in preclinical testing.

16 with CRLF2-rearranged ALL and merit further preclinical testing.

17 xenograft models of human retinoblastoma for preclinical testing.

18 d before they can be recommended for further preclinical testing.

19 d by NIH contracts issued in 2004 are now in preclinical testing.

20 ges, each system plays a significant role in preclinical testing.

21 In preclinical testing, 2-hydroxypropyl-beta-cyclodextrins

22 ne antigens were derived and warrant further preclinical testing against clinically relevant C. diffi

23 nimal model of GBM strongly supports further preclinical testing and downstream process development o

24 y promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail

25 n clinical trials has been due to inadequate preclinical testing and flawed clinical development prog

26 unners of antagonists that proceeded through preclinical testing and into large patient trials to tre

27 ith MCB should be useful for drug discovery, preclinical testing and mechanistic investigation of hum

28 rther study of hepatic tumorigenesis and for preclinical testing, and identify a subset of human hepa

29 in should greatly facilitate the generation, preclinical testing, and manufacturing of attenuated hMP

30 tor cells in differentiation, tumorigenesis, preclinical testing, and the development of drug resista

31 Despite a solid rationale and encouraging preclinical testing, aquaretics have not improved clinic

32 none derivative that is undergoing extensive preclinical testing as a potential anticancer drug.

33 oxygenated co-cultures stabilizes overnight, preclinical testing can be carried out days or even week

34 As predicted in preclinical testing, daily oral LY353381.HCl is safe, is

35 Most drugs that pass preclinical tests fail in these patients, emphasizing th

36 ctical, readily standardized live-animal and preclinical test for ovine scrapie.

37 otypes in the shaker1 RPE represents a valid preclinical test for potential therapeutic treatments.

38 Several promising drugs are in preclinical testing for FXS; however, bench-to-bedside p

39 is commentary, we discuss recent advances in preclinical testing for pediatric cancer and provide rec

40 l as in the design of better high-throughput preclinical tests for assessing the proarrhythmic effect

41 is a promising addition to the repertoire of preclinical tests for drug-induced repolarization abnorm

42 of naturally occurring cancers in dogs as a preclinical testing ground for telomerase targeted thera

43 and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.

44 or DYT1 dystonia and establish the basis for preclinical testing in animal models of the disease.

45 accelerate drug development by streamlining preclinical testing in laboratory animals.

46 with FcgammaR contributed to the failure of preclinical testing in macaques to predict toxicity in h

47 Preclinical tests in monkeys defined sites of vaccine vi

48 atment for this deadly disease, we conducted preclinical tests in ovarian tumor-bearing mice to evalu

49 ns of advisory bodies; antigen discovery and preclinical testing, including live vector systems expre

50 IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor pho

51 cers in cell culture and in mouse models for preclinical testing is a challenge that has not yet been

52 Failure to predict hepatotoxic drugs in preclinical testing makes it imperative to develop bette

53 Preclinical testing of a mixed chimerism mediated organ

54 oint in systemic models of RA as well as for preclinical testing of antiinflammatory therapies.

55 rring malignancies such as osteosarcoma, for preclinical testing of antineoplastic agents offers sign

56 studies and assayed their applicability for preclinical testing of antiviral compounds.

57 Finally, preclinical testing of AZD1208 in a mouse model of ATL r

58 health and disease and to achieve predictive preclinical testing of both prevention measures and pote

59 Preclinical testing of candidate microbicides for the pr

60 Preclinical testing of chemical and physical modulation

61 olavirus is currently available, progress in preclinical testing of countermeasures has been made.

62 ine skin is the most commonly used model for preclinical testing of dermal formulations.

63 s of DENV infection and pathogenesis and for preclinical testing of drug and vaccine candidates.

64 ing through microphysiological platforms for preclinical testing of drugs and modeling of disease tha

65 investigating tuberculosis pathogenesis and preclinical testing of drugs and vaccines.

66 le myeloma may provide new opportunities for preclinical testing of drugs for treatment of the human

67 The development of therapies for HD requires preclinical testing of drugs in animal models that repro

68 int to a new paradigm for identification and preclinical testing of future ALS therapeutics.

69 ector system that should allow comprehensive preclinical testing of HIV-1-based therapeutic vectors i

70 Preclinical testing of human therapeutic monoclonal anti

71 dicate that the rabbit is a useful model for preclinical testing of intranasal meningococcal NOMV vac

72 The in vivo preclinical testing of investigational therapies for mul

73 for studying ovarian cancer biology and for preclinical testing of molecularly targeted therapeutics

74 Preclinical testing of MUC1 vaccines revealed existence

75 r analysis of the pathophysiology of CHD and preclinical testing of new approaches for the prevention

76 Development and preclinical testing of new cancer therapies is limited b

77 The model will be useful for preclinical testing of new methods of long-term corneal

78 s somatic mouse model may also be useful for preclinical testing of new prophylactic and therapeutic

79 ease in murine modeling of CG, and promising preclinical testing of new therapeutic strategies sugges

80 odulators and provide a crucial platform for preclinical testing of new therapies.

81 apeutically and have provided a platform for preclinical testing of novel candidate therapies.

82 racterized here offers a powerful system for preclinical testing of novel drugs and drug combinations

83 in patient tumors ex vivo, thereby enabling preclinical testing of novel drugs and helping stratify

84 humanized mouse model may thus be useful for preclinical testing of novel human NK cell-targeted and

85 cally meaningful but underutilized model for preclinical testing of novel strategies for aggressive h

86 This method should afford the means for preclinical testing of novel therapeutic approaches to t

87 n of malignant mesothelioma pathogenesis and preclinical testing of novel therapeutic modalities.

88 ning to accelerate the pace of discovery and preclinical testing of p53 in animal models.

89 Furthermore, these animals may be useful for preclinical testing of potential genetic and/or pharmaco

90 etter understand its pathophysiology and for preclinical testing of potential therapeutic agents.

91 ia and industry for more clinically relevant preclinical testing of potential therapeutic targets and

92 d the establishment of a system for rigorous preclinical testing of promising cardioprotective agents

93 Our findings support the preclinical testing of PTP1B inhibitors for prostate can

94 n this article, we will summarize results on preclinical testing of selective and nonselective single

95 Preclinical testing of seroconversion panels showed that

96 w recent progress in the rational design and preclinical testing of small molecules that induce selec

97 uggesting that this is a useful approach for preclinical testing of such agents.

98 in solid tumor biology and set the stage for preclinical testing of targeted therapeutic approaches.

99 e of human tumors and thus may be useful for preclinical testing of targeted therapy for patients wit

100 cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a va

101 e the molecular pathogenesis of AITL and for preclinical testing of therapies aimed at targeting dysr

102 e models are rationale candidates for use in preclinical testing of therapies focused on these biolog

103 Currently, preclinical testing of therapies for hepatoblastoma (HB)

104 Preclinical testing of these vectors has thus far been l

105 del can potentially be developed further for preclinical testing of vaccine candidates.

106 ese challenge stocks should prove useful for preclinical testing of vaccines and other interventions

107 Thus, this humanized mouse model permits preclinical testing of vaccines designed to induce cellu

108 ow a new approach to the rational design and preclinical testing of vaccines that cannot be tested in

109 cation of target and off-target effects, and preclinical testing on relevant cell types for the patho

110 ation and validation and culminated with the preclinical tests on animal disease models.

111 models of AGRIN-related CMS that would allow preclinical testing or studies of postnatal disease prog

112 In preclinical testing, oral gefitinib inhibited the growth

113 In preclinical testing over a decade, the authors developed

114 iotic cell lines and chimeric mouse model as preclinical testing platform, our results, to our knowle

115 anded dependence receptors are in late-stage preclinical tests, poised for clinical evaluation.

116 nalyzed 67 agents evaluated by the Pediatric Preclinical Testing Program to determine whether a singl

117 ity in several tumor models in the Pediatric Preclinical Testing Program.

118 In preclinical testing, SGN-CD33A is more potent than GO ag

119 uman clinical studies require production and preclinical testing that are the same as vaccines enteri

120 ut also describe a valuable animal model for preclinical testing that is coupled with a primary cell-

121 or breast and lymph node imaging, leading to preclinical testing that will produce results that bette

122 CNS indications is hampered by a paucity of preclinical tests that accurately predict drug efficacy

123 Following inconspicuous preclinical testing, the superagonistic anti-CD28 mAb TG

124 tion of product-specific characteristics and preclinical testing to determine whether there is suffic

125 scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II cli

126 practice is hindered by the lack of thorough preclinical testing using representative animal models a

127 Preclinical testing was performed of an optical breast l